Related Experiment Videos
Prevention of intraventricular haemorrhage in preterm infants by phenobarbitone. A controlled trial
Insights
Phenobarbitone administration significantly reduced the incidence of periventricular/intraventricular haemorrhage (IVH) in very low birth weight infants. This study suggests phenobarbitone as a potential prophylactic agent for IVH in preterm neonates.
Area of Science:
- Neonatalogy
- Pediatric Neurology
- Pharmacology
Background:
- Periventricular/intraventricular haemorrhage (IVH) is a serious complication in preterm infants.
- Identifying effective preventative strategies for IVH is crucial for improving neonatal outcomes.
Purpose of the Study:
- To investigate the efficacy of phenobarbitone in reducing the incidence of IVH in infants with birth weights less than 1500 g.
Main Methods:
- A randomized controlled trial involving sixty infants with birth weights <1500 g.
- Infants were assigned to either a phenobarbitone group or a control group.
- Phenobarbitone was administered intravenously to achieve therapeutic serum levels, with maintenance therapy for one week.
Main Results:
- The incidence of IVH was significantly lower in the phenobarbitone group (13.3%) compared to the control group (46.7%).
- Risk factors associated with IVH were comparable between the two study groups.
- Phenobarbitone treatment was well-tolerated, achieving anticonvulsant serum levels within 12-18 hours.
Conclusions:
- Phenobarbitone administration appears to be an effective prophylactic measure against periventricular/intraventricular haemorrhage in small preterm infants.
- The findings suggest a potential role for phenobarbitone in the management of high-risk neonates to prevent IVH.
- Further research may be warranted to confirm these findings and establish optimal dosing regimens.
Abstract:
Sixty infants with birth-weights less than 1500 g and who were less than 6 h old were randomly assigned to a group given phenobarbitone or a control group. Intravenous phenobarbitone was given in doses sufficient to achieve anticonvulsant serum levels within 12-18 h. Maintenance therapy was continued for one week. Periventricular/intraventricular haemorrhage (IVH) occurred in 13.3% (4/30) of the phenobarbitone group and in 46.7% (14/30) of the control group. The occurrence of risk factors related to IVH was similar in the two groups. Phenobarbitone may reduce the incidence of IVH in small preterm infants.